Involvement of interleukin-15 and interleukin-21, two γ-chain-related cytokines, in celiac disease

Daniela De Nitto, Ivan Monteleone, Eleonora Franzè, Francesco Pallone, Giovanni Monteleone

Abstract
Celiac disease (CD), an enteropathy caused by dietary gluten in genetically susceptible individuals, is histologically characterized by villous atrophy, crypt cell hyperplasia, and increased number of intra-epithelial lymphocytes. The nature of CD pathogenesis remains unclear, but recent evidence indicates that both innate and adaptive immune responses are necessary for the phenotypic expression and pathologic changes characteristic of CD. Extensive studies of molecules produced by immune cells in the gut of CD patients have led to identification of two cytokines, namely interleukin (IL)-15 and IL-21, which are thought to play a major role in orchestrating the mucosal inflammatory response in CD. Here we review the current knowledge of the expression and function of IL-15 and IL-21 in CD.

© 2009 The WJG Press and Baishideng. All rights reserved.

Key words: Interleukin-21; Interleukin-15; Celiac disease

INTRODUCTION
Celiac disease (CD) is a chronic gastrointestinal disorder caused, in genetically predisposed individuals, by ingestion of the gluten proteins of wheat, rye, and barley. The prevalence of CD is approximately 1% in the Western world[1-3]. The disease is strongly associated with HLA-DQ genes. Most patients carry a variant of DQ2 (alleles DQA1*05/DQB1*02) and others carry a variant of DQ8 (alleles DQA1*03/DQB1*0302)[4,5]. These haplotypes are relatively common in the healthy population, and only 1:20 individuals who express HLA-DQ2/DQ8 have CD[4,5]. These observations and the fact that the concordance rate between HLA-identical siblings is much lower than between monozygotic twins suggest that most probably other non-HLA genes are involved in the pathogenesis of CD[6-8].

In CD patients, ingestion of gluten triggers a mucosal inflammatory response, which leads to the tissue damage. The histological features of CD are villous atrophy, crypt cell hyperplasia, and increased number of intra-epithelial lymphocytes (IELs). The clinical manifestations can range from asymptomatic to severe malabsorption. Patients can also manifest symptoms of other immune-mediated diseases, which can associate with CD. The only treatment is a lifelong gluten-free diet, which results, in the vast majority of patients, in complete remission of symptoms and recovery of the normal mucosal histology[9].

Although the pathogenesis of CD is not fully understood, it is known that gluten peptides are deamidated by tissue transglutaminase and presented by DQ2 or DQ8 antigen-presenting cells to lamina propria CD4+ T cells[10,11]. Upon activation, CD4+ T cells polarize along the T helper (Th)1-type pathway, as substantiated by their ability to produce large amounts of interferon (IFN)-γ, the signature cytokine of Th1 responses[11,12]. In CD patients on a gluten-free diet, IFN-γ production is as low as in healthy controls but it can be stimulated in vitro by gluten to reach levels of untreated CD patients. In these mucosal cultures, neutralization of IFN-γ prevents gliadin-mediated...
morphological changes thus supporting the role of the adaptive immune response and IFN-γ in CD immunopathology\cite{11,12}. More recently, it has become clear that some gluten peptides can induce mucosal damage by directly activating innate immune mechanisms\cite{13}. These observations collectively underlie the complexity of the pathogenic mechanism in CD and suggest that the CD-associated mucosal damage relies on the activation of multiple rather than single cell pathways.

**GLUTEN PEPTIDES STIMULATE INNATE IMMUNITY AND CAUSE EPITHELIAL DAMAGE VIA AN INTERLEUKIN (IL)-15-DEPENDENT MECHANISM**

It has long been known that gluten peptides cause epithelial damage when added to ex vivo organ cultures of biopsies taken from CD patients on a gluten-free diet, but not from controls\cite{14}. As previously mentioned, this pathogenic response was initially thought to be secondary to the activation of lamina propria CD4+ T cells and production of inflammatory cytokines, such as IFN-γ\cite{15}. However, more recently Maiuri et al\cite{16} showed that the gluten p31-43 peptide is able to induce mucosal damage by directly activating innate immune cells. In particular, it was shown that the p31-43 peptide elicits the production of IL-15 by lamina propria macrophages and dendritic cells in ex vivo organ cultures of CD biopsies, thus triggering a sequence of events that culminates in epithelial damage (Figure 1). These findings correlate well with the demonstration that IL-15 is over-expressed in both the lamina propria and intestinal epithelium of patients with active, untreated CD as compared with normal controls or inactive, gluten-free diet treated CD patients\cite{15,16}.

The majority of intestinal IELs are T cell receptor (TcR)αβ+ CD8+ CD4+ and a significant proportion are TcRγδ+ CD8+ CD4+. IELs express a variety of natural killer (NK) lineage receptors, supporting their involvement in epithelial cell damage\cite{17}. Corroborating Maiuri’s results, Hüb et al\cite{18} showed that treatment of biopsies taken from inactive CD patients with the gluten p31-49 peptide enhances the enterocyte expression of the non-conventional HLA molecules MICA/B. MIC molecules are known to be induced on enterocytes by stress and are up-regulated in active CD mucosa\cite{19}. MICA/B are ligands of the activating NKG2D receptor, which signals through the adapter protein DAP10 and is expressed on most NK cells, CD8+ TcRαβ+ and TcRγδ+, but normally not on CD4+ T cells\cite{20,21}. Expression of NKG2D in IELs is increased in active CD mucosa, and IELs lyse epithelial cells via NKG2D\cite{22}. Up-regulation of MICA/B molecules also occurs in CD biopsies treated with exogenous IL-15, and a neutralizing IL-15 antibody blocks the gluten-mediated MIC-inducing effect in organ cultures of CD biopsies\cite{23,24}. Meresse et al\cite{25} showed that IL-15 also enhances the expression of both NKG2D and DAP10 in IELs, and that the cytoplasmic attack of the epithelium by IELs may be perpetuated via NKG2D independently of TcR specificity (Figure 1). Taken together these findings emphasize the critical role of IL-15 in intestinal epithelial cell death induced by NKG2D-expressing IELs.

**IL-15 AND COUNTER-REGULATORY MECHANISMS IN CD**

In the gut, mucosal homeostasis arises from a highly dynamic balance between host protective immunity and regulatory mechanisms\cite{26}. One such counter-regulatory mechanism involves transforming growth factor-β1 (TGF-β1), a cytokine that is able to exert a number of negative effects on immune cells, including inhibition of T cell proliferation and differentiation, as well as down-regulation of macrophage activation and dendritic cell maturation\cite{27}. Consistently, mice with global TGF-β1 defects, such as TGF-β1-deficient mice or transgenic mice expressing a dominant-negative TGF-βR II chain that are unresponsive to TGF-β1 signaling, develop intestinal mucosal inflammation\cite{28,29}. On the other hand, studies in mouse models of gut inflammation have shown that production of TGF-β1 is consistently associated with greatly diminished severity of inflammation\cite{30}. Because TGF-β1 regulates both lymphoid and myeloid cells\cite{31}, several researchers have examined the expression and activity of TGF-β1 in chronic gastrointestinal inflammatory diseases, including CD. Initial studies conducted by Lahat et al\cite{32} showed that in active CD mucosa there was enhanced expression of transcripts for TGF-β1 as compared to controls. In contrast, Lionetti et al\cite{33} reported that the total RNA expression of TGF-β1 did not differ between active CD and controls. However, in active CD, TGF-β1 production was mostly confined to lamina propria T cells and macrophages, while in controls it was mostly produced by epithelial cells\cite{34}. TGF-β1 initiates signaling through the ligand-dependent activation of a complex of heterodimeric transmembrane serine/threonine kinases, consisting of type I (TGF-βR I) and type II (TGF-βR II) receptors\cite{35}. Upon TGF-β1 binding there is phosphorylation and activation of TGF-βR I by the constitutively active and auto-phosphorylating TGF-βR II chain. TGF-βR I in turn phosphorylates two proteins, termed Smad 2 and Smad 3. Once phosphorylated, Smad2 and Smad3 associate with Smad4 and translocate to the nucleus where Smad complex participates in transcriptional control of target genes\cite{36}. This pathway has been reported to be antagonized by inflammatory cytokines, which can impair the regulatory functions of TGF-β1 and alter immune homeostasis\cite{31,32}. Therefore, it is conceivable that, during chronic inflammatory processes, there may be deficient TGF-β1 activity despite this cytokine being highly produced. In line with this, Benahmed et al\cite{37} have recently shown that TGF-β1 inhibited the proliferative response of normal intestinal IELs and lamina propria

www.wjgnet.com
lymphocytes induced by IL-2 but not that triggered by IL-15. The inhibitory effect of IL-15 on TGF-β1 activity was substantiated further by the demonstration that IL-15 impaired the formation of Smad3-DNA complexes in response to TGF-β1 stimulation[33].

In contrast, IL-15 enhanced the activation of the Janus kinase (JNK) pathway thus promoting the inhibitory effect of phospho-c-jun on the formation of Smad-DNA complexes. Further analysis revealed that the transcription levels of tristetraprolin, a TGF-β target gene under the control of the Smad3 pathway, were decreased in duodenal biopsies from patients with active CD compared with controls. This defect was associated with no significant change in the intracellular levels of phosphorylated Smad3 and Smad7, clearly indicating that initial steps of TGF-β signaling are preserved[34,35]. Moreover, treatment with no significant change in the intracellular levels of phosphorylated Smad3 and Smad7, clearly indicating that initial steps of TGF-β signaling are preserved[34,35].

This is in contrast to the Smad7-dependent inhibition of TGF-β1/Smad3 signaling described in patients with inflammatory bowel diseases[36,37].

IELs, lamina propria lymphocytes, and epithelial cells of active CD contain high levels of phospho-c-jun, and inhibition of this protein in organ cultures of CD biopsies enhances tristetraprolin expression[38]. Moreover, treatment of organ cultures of CD biopsies with anti-IL-15 reduces phospho-c-jun and increases tristetraprolin, thus confirming the prominent role of IL-15 in the phospho-c-jun-mediated inhibition of TGF-β1 signaling[39].

While NKG2C and NKG2D are activating NK receptors, NKG2A is considered an inhibiting NK receptor. NKG2A can associate with CD94 and bind the non-classical MHC Ib molecule, HLA-E, which is expressed on epithelial cells of CD patients but not on epithelial cells of healthy individuals[36,37]. Although NKG2A competes with NKG2C for its interaction with HLA-E, the former has a higher binding affinity for HLA-E compared with NKG2C. Upon binding to this ligand, CD94/NKG2A delivers negative signals to cytotoxic cells[39]. A higher percentage of small intestinal TcRγδ IELs express CD94/NKG2A compared with TcRαβ IELs, and TcRγδ IELs exert negative effects on the IL-15-mediated induction of IFN-γ, granzyme B, and NKG2D in CD8+ TcRαβ IELs[40]. These observations suggest that TcRγδ IELs have the ability to suppress the cytotoxic programming of TcRαβ IELs. This inhibitory effect requires interaction of NKG2A with its ligand HLA-E, a phenomenon which is followed by enhanced secretion of TGF-β1. Notably, blockade of TGF-β1 activity with a neutralizing human TGF-β1 antibody partially abrogates the suppressive capability of TcRγδ IELs, and exogenous TGF-β1 dose-dependently inhibits the IL-15-mediated induction of IFN-γ, granzyme B, and NKG2D in CD8+ TcRαβ IELs[40]. Therefore, in this cell context, IL-15 is not sufficient to abrogate the immunosuppressive action of TGF-β1. These findings conflict with the aforementioned data published by Benahmed et al.[41]. It is likely that this discrepancy may simply be due to differences in cell culture conditions used in these two studies. Another possibility is that the IL-15-mediated negative regulation of TGF-β1 signaling occurs only in specific cell types. Since TGF-β1 can trigger both Smad-dependent and -independent intracellular pathways[40,41], it is also plausible that IL-15 can interfere with some and not all TGF-β1-activated signals.

Expression of NKG2A is decreased on TcRαβ IELs and TcRγδ IELs from CD patients as compared to normal subjects[39,41]. The mechanism that removes this negative regulator from CD IELs remains unknown. NKG2A possesses in its promoter a binding site for...
Smad3, and there is evidence that TGF-β1 cooperates with the TcR in enhancing the expression of NKG2A on CD8+ T cells\[53]. Therefore, molecules that disrupt TGF-β1 signaling could, at least in theory, contribute to the down-regulation of NKG2A in CD. IL-15 is not able to directly regulate NKG2A expression\[49], even though it remains possible that it could inhibit the TGF-β1-induced NKG2A expression.

**IL-21 as a positive regulator of Th1 cell response in CD**

The demonstration that CD lesions are associated with a marked infiltration of IFN-γ-secreting cells has boosted intensive research aimed at identifying the factors that promote the ongoing mucosal Th1 cell response. Paradoxically, IL-12, the major Th1-inducing factor in man, is not over-produced in CD mucosa\[12]. However, analysis of transcription factors that drive Th cell differentiation revealed that in active CD mucosa there is enhanced expression of T-bet, a member of the T-box family of transcription factors that directs Th1 lineage commitment and is essential for IFN-γ production in CD4+ T cells\[50,51]. In contrast, no increase in GATA3 and active STAT6, two transcription factors that specifically regulate Th2 differentiation, is seen in active CD samples as compared to controls\[49,52]. Interestingly, active CD biopsies do not exhibit enhanced activation of STAT4\[53], an IL-12-dependent Th1-inducing transcription factor, thus confirming the lack of IL-12 activity. These data strongly support the existence of a regulatory pathway for Th1 differentiation that starts from activation of T-bet and is independent of IL-12-driven STAT-4 signaling. So the critical question is: what induces and sustains T-bet in CD? We have recently shown that in the duodenal mucosa of patients with active but not inactive CD there is enhanced production of IL-21\[54]. Interestingly, neutralization of IL-21 activity in ex vivo organ cultures of CD biopsies reduces both T-bet expression and IFN-γ production\[55]. Since IFN-γ enhances T-bet via a STAT1-dependent mechanism\[51,52], it is tempting to speculate that IL-21 is part of a positive feedback loop that helps amplify and stabilize the committed Th1 cell phenotype in CD (Figure 1).

Recent genome-wide association studies have provided convincing evidence that the chromosomal 4q27 region harboring the IL-2 and IL-21 genes is associated with CD\[55]. A similar genetic association has been described in other immune-mediated diseases, such as psoriasis, type 1 diabetes, and inflammatory bowel diseases\[53,56]. However, it is not yet known if such polymorphisms can influence the tissue levels of IL-21.

Biopsies taken from CD patients on a gluten-free diet over-express IL-21 when challenged in vitro with gluten peptides\[57]; however, the basic mechanisms that control the expression of IL-21 in CD mucosa remain to be elucidated. Previously, we showed that IFN-α is up-regulated in the mucosa of active CD patients, where it most probably contributes to intensifying IFN-γ production\[44,58]. Indeed, neutralization of IFN-α activity drastically reduces the gliadin peptide-driven IFN-γ expression in biopsies of inactive CD patients\[44]. Interestingly, IFN-α enhances the mRNA expression of IL-21 in activated human T cells\[49], thus suggesting a role for this cytokine in the positive control of IL-21 in CD (Figure 1).

**Potential involvement of IL-21 in the activity of other mucosal cell types**

The biological functions of IL-21 are mediated by a cell-surface class I cytokine receptor, formed by the common γ-chain subunit (shared with IL-2, IL-4, IL-7, IL-9, IL-13 and IL-15 receptors) and its own unique receptor (designated IL-21 receptor)\[55]. Since this receptor is expressed by both immune and non-immune cells, it is plausible that IL-21 maintains chronic inflammation and/or favors tissue damage in CD by targeting additional cell types other than Th1 lymphocytes. In fact, IL-21 has been shown to stimulate epithelial cells to secrete chemokines and facilitate recruitment of immune cells within the inflamed tissue, induce fibroblasts to make tissue-damaging proteases, and make effector CD4+ T cells resistant to regulatory T cell-mediated immunosuppression\[59,60]. In light of the role of IL-21 in the control of B cell and plasma cell function\[49], IL-21 may also contribute to the production of CD-associated autoantibodies. Since its discovery, it has become clear that IL-21 is also able to modulate the proliferation and/or effector function of CD8+ T cells and NK cells\[61]. Using IELs isolated from human jejunal mucosa, Ebert has recently shown that IL-21 increases perforin-mediated cytotoxicity and serine esterase release without affecting the growth and survival of these cells\[62]. The relevance of this finding for CD pathogenesis remains to be ascertained, although IL-21-mediated cytotoxic T cell activation could contribute to the intestinal epithelial cell death and villous atrophy in CD.

**CONCLUSION**

A growing body of evidence suggests that IL-15 and IL-21 may play important roles in the immune response associated with inflammation and tissue damage in CD, even though some intriguing questions remain to be resolved. For instance, it remains to be determined whether these two cytokines contribute qualitatively and quantitatively differently to the initiation and progress of the inflammatory cascade in CD. The fact that IL-15 and IL-21 share a receptor subunit and target the same cell types raises the possibility that these cytokines may cooperate in regulating specific cell immune responses. Indeed, both IL-15 and IL-21 are known to stimulate the growth of T cells, enhance the production of IFN-γ by Th1 cells, and promote the activation of cytotoxic cells\[46,51]. As outlined in this article, these two cytokines might also act in concert to disrupt local mechanisms of immune tolerance. This hypothesis is supported by the demonstration that IL-15 inhibits TGF-β1 activity, and IL-21 renders effector CD4+ T cells resistant to the suppressive effects of CD4+CD25+ regulatory T cells\[33,34]. Nonetheless it is noteworthy that...
IL-15 and IL-21 seem to differentially modulate some aspects of both innate and adaptive immunity, such as dendritic cell maturation and T cell apoptosis. Therefore, we cannot exclude the possibility that, at least in some stages of the inflammatory process, IL-15 and IL-21 can exert opposing effects on the gluten-driven immune response.

REFERENCES

1. Bingley PJ, Williams AJ, Norcross AJ, Unsworth DJ, Lock RJ, Ness AR, Jones RW. Undiagnosed coeliac disease at age seven: population based prospective birth cohort study. BMJ 2004; 328: 322-323
2. Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, Elitsur Y, Green PH, Guandalini S, Hill ID, Pietzak M, Ventura A, Thorpe M, Kryszak D, Foranello SS, Fawcett MJ, Murray JA, Horvath K. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003; 163: 286-292
3. Mäki M, Mustalathi K, Kokkonen J, Kumpulainen H, Alitalo R, Hämäläinen P, Järvelä J, Karila E, Alitalo K, Due R, Ahonen P, Jouhki V, Järvi H, Kauppila A, Norrild B, Saarnio K, Saarinen K, Vaheri A, Virtanen M. Prevalence of celiac disease among children in Finland. N Engl J Med 2003; 348: 2517-2524
4. Louka AS, Sollid LM. HLA in coeliac disease: unravelling the complex genetics of a complex disorder. Tissue Antigens 2003; 61: 105-117
5. Karella S, Louka AS, Moodie SJ, Asher H, Clot F, Greco L, Ciclitira PJ, Sollid LM, Partanen J. HLA types in coeliac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 2003; 64: 469-477
6. Greco L, Romino R, Coto I, Di Cosmo N, Perocci S, Maglio M, Paparo F, Gasperi V, Limongelli MG, Cotighin S, D'Agate C, Tinto N, Sacchetti L, Tosi R, Stazi MA. The first large population based twin study of coeliac disease. Gut 2002; 50: 624-628
7. van Heel DA, Franke L, Hunt KA, Vithiell R, Sherlock M, Zhernakova A, Nieuwveen B, Wapenaar MC, Barnett RC, Bethel G, Holmes GK, Feighery C, Jewell D, Kelleher D, Kumar P, Travis S, Walters JR, Sanders DS, Howdle P, Swift J, Playford RJ, McLaren WM, Mealin ML, Mulder CJ, McManus R, McGinnis R, Carum LD, Deloukas P, Wijmenga C. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007; 39: 827-829
8. Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Brunnenberg M, Romanos J, Diesen LC, Ryan AW, Panesar D, Greco L, Takeuchi F, McLaren WM, Holmes GK, Howdle PD, Walters JR, Sanders DS, Playford RJ, Trynka G, Mulder CJ, Mealin ML, Verbeek WH, Trimble V, Steven FM, O'Morain C, Kennedy NP, Kelleher D, Pennington DJ, Strachan DP, Mcardle WL, Mein CA, Wapenaar MC, Deloukas P, McGinnis R, McManus R, Wijmenga C, van Heel DA. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008; 40: 395-402
9. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009; 373: 1480-1493
10. Sjöström H, Lundin KE, Molberg O, Körner R, McAdams SN, Anthonsen D, Quarsten H, Norén O, Roepstorff P, Thorsby E, Sollid LM. Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition. Scand J Immunol 1998; 48: 111-115
11. Nilsen EM, Lundin KE, Krajcí P, Scott H, Sollid LM, Brandtzaeg P. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 1995; 37: 766-776
Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999; 397: 710-713

Bitzner M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bittinger EP. A mechanism of suppression of TGF-beta/SMAD signalling by NF-kappa B/RelA. Genes Dev 2000; 14: 187-197

Benahmed M, Meresse B, Arnulf B, Barbe U, Mention JJ, Verkarre V, Allez M, Cellier C, Hermine O, Cerf-Bensussan N. Inhibition of TGF-beta signalling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology 2007; 133: 994-1008

Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta signaling in chronic inflammatory bowel disease. J Clin Invest 2008; 118: 601-609

Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol 2004; 25: 513-517

Jabri B, Meresse B. NGK2 receptor-mediated regulation of effector CTL functions in the human tissue microenvironment. Curr Top Microbiol Immunol 2006; 298: 139-156

Jabri B, de Serre NP, Cellier C, Evans K, Gache C, Carvalho M, Mougenot JF, Allez M, Jian R, Desreumaux P, Colombel JF, Matuchansky C, Cugnenc H, Lopez-Botet M, Vivier E, Moretta A, Roberts AI, Bortolotti E, Guy-Grand D, Brousse V, Schmitz J, Cerf-Bensussan N. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2003; 124: 710-713

Parrish-Novak J, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Spirakis A, Land K, Brandt C, Kuijper JL, Bussel JB, Halkin O, Achkar JP, Xavier RJ, Daly MJ, Duerr RH, Wijmenga N, Lian J, Lefebvre C, Brant SR, Cho JH, Silverberg MS, Taylor KD, de Jong DJ, Stokkens PC, McGovern D, Palmieri O, Ackbar JP, Xavier RJ, Daly MJ, Duerr RH, Wijmenga C, Weersma RK, Rioux JD. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009; 58: 799-804

Monteleone G, Pender SL, Alstead E, Hauer AC, Lionetti P, McKenzie C, MacDonald TT. Role of interferon alpha in promoting T helper cell type I responses in the small intestine in coeliac disease. Gut 2001; 48: 425-429

Di Sabatino A, Pickard KM, Gordon JN, Salvati V, Mazzarella G, Beattie RM, Vossenkaemper A, Roveddi L, Leakey NA, Croft NM, Troncone R, Corazza GR, Stagg AJ, Monteleone G, MacDonald TT. Evidence for the role of interferon-alpha production by dendritic cells in the TH1 response in celiac disease. Gastroenterology 2007; 133: 1175-1187

Striegel M, Jullumlen I, Matikainen S. IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol 2004; 76: 416-422

Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Ann Rev Immunol 2008; 26: 57-79

Caruso F, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V, Caprioli F, Del Vecchio Bianco G, Paoluzzi OA, MacDonald TT, Pallone F, Monteleone G. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007; 132: 166-175

Monteleone G, Caruso F, Fina D, Peluso I, Gioia V, Stolfi C, Fantini MC, Caprioli F, Tersigni R, Alessandroni L, MacDonald TT, Pallone F. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006; 55: 1774-1780

Peluso I, Fantini MC, Fina D, Caruso R, Boirivant M, MacDonald TT, Pallone F, Monteleone G. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007; 178: 732-739

Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, Noubade R, Briso EM, Charland C, Leonard WJ, Ciliberto G, Teuscher C, Haynes L, Rincon M. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by IL-21 producing cells. J Exp Med 2008; 209: 69-78

Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhedt S, Heipel M, Brandt C, Kuiper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiotia F, Bort S, Hambley K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2004; 408: 57-63

Ebert EC. Interleukin 21 up-regulates perforin-mediated cytotoxic activity of human intra-epithelial lymphocytes. Immunology 2009; 127: 206-215

Mclnnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4: 392-397